← Back to Clinical Trials
Recruiting NCT06215235

Implementation of Bright Light Therapy ID

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Depressive Symptoms
Sponsor Erasmus Medical Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 105
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-10-18
Completion 2025-12
Interventions
Bright light therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Many adults with intellectual disabilities (ID) have depressive symptoms, which negatively impact their quality of life. A lot of of the non-medicinal forms of treatment are not or hardly suitable for people with ID. Bright light therapy (BLT) seems to be a good option. Earlier research has shown that BLT is applicable in this group and seems promising in terms of reducing depressive symptoms, without serious side effects. In part 1 of this project we investigate the implementation of BLT at Amarant. We will take the lessons learned into part 2 of this project: the implementation of BLT at Abrona. We will evaluate this process and the outcomes.

Eligibility Criteria

Inclusion Criteria: * Involved in the implementation of BLT (staff) OR * Involved in the prescription or application of BLT (staff/relatives) OR * receiving BLT for their depressive symptoms (patients with ID) * 18 years or older * informed consent Exclusion Criteria: * n/a

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}